375 related articles for article (PubMed ID: 33910214)
21. Dynamic modelling of the PI3K/MTOR signalling network uncovers biphasic dependence of mTORC1 activity on the mTORC2 subunit SIN1.
Ghomlaghi M; Yang G; Shin SY; James DE; Nguyen LK
PLoS Comput Biol; 2021 Sep; 17(9):e1008513. PubMed ID: 34529665
[TBL] [Abstract][Full Text] [Related]
22. mTORC1 and mTORC2 are differentially engaged in the development of laser-induced CNV.
Yang JY; Madrakhimov SB; Ahn DH; Chang HS; Jung SJ; Nah SK; Park HY; Park TK
Cell Commun Signal; 2019 Jun; 17(1):64. PubMed ID: 31200728
[TBL] [Abstract][Full Text] [Related]
23. Growing knowledge of the mTOR signaling network.
Huang K; Fingar DC
Semin Cell Dev Biol; 2014 Dec; 36():79-90. PubMed ID: 25242279
[TBL] [Abstract][Full Text] [Related]
24. Differential localization and anabolic responsiveness of mTOR complexes in human skeletal muscle in response to feeding and exercise.
Hodson N; McGlory C; Oikawa SY; Jeromson S; Song Z; Rüegg MA; Hamilton DL; Phillips SM; Philp A
Am J Physiol Cell Physiol; 2017 Dec; 313(6):C604-C611. PubMed ID: 28971834
[TBL] [Abstract][Full Text] [Related]
25. Twenty-five years of mTOR: Uncovering the link from nutrients to growth.
Sabatini DM
Proc Natl Acad Sci U S A; 2017 Nov; 114(45):11818-11825. PubMed ID: 29078414
[TBL] [Abstract][Full Text] [Related]
26. Dynamic modeling of signal transduction by mTOR complexes in cancer.
Dorvash M; Farahmandnia M; Mosaddeghi P; Farahmandnejad M; Saber H; Khorraminejad-Shirazi M; Azadi A; Tavassoly I
J Theor Biol; 2019 Dec; 483():109992. PubMed ID: 31493485
[TBL] [Abstract][Full Text] [Related]
27. Autoregulation of the mechanistic target of rapamycin (mTOR) complex 2 integrity is controlled by an ATP-dependent mechanism.
Chen CH; Kiyan V; Zhylkibayev AA; Kazyken D; Bulgakova O; Page KE; Bersimbaev RI; Spooner E; Sarbassov DD
J Biol Chem; 2013 Sep; 288(38):27019-27030. PubMed ID: 23928304
[TBL] [Abstract][Full Text] [Related]
28. Regulation of mTOR Signaling: Emerging Role of Cyclic Nucleotide-Dependent Protein Kinases and Implications for Cardiometabolic Disease.
Shi F; Collins S
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511253
[TBL] [Abstract][Full Text] [Related]
29. Convergent and Divergent Mechanisms of Epileptogenesis in mTORopathies.
Nguyen LH; Bordey A
Front Neuroanat; 2021; 15():664695. PubMed ID: 33897381
[TBL] [Abstract][Full Text] [Related]
30. Hyperactivity of mTORC1- and mTORC2-dependent signaling mediates epilepsy downstream of somatic PTEN loss.
Cullen ER; Safari M; Mittelstadt I; Weston MC
Elife; 2024 Mar; 12():. PubMed ID: 38446016
[TBL] [Abstract][Full Text] [Related]
31. Cryo-EM structure of human mTOR complex 2.
Chen X; Liu M; Tian Y; Li J; Qi Y; Zhao D; Wu Z; Huang M; Wong CCL; Wang HW; Wang J; Yang H; Xu Y
Cell Res; 2018 May; 28(5):518-528. PubMed ID: 29567957
[TBL] [Abstract][Full Text] [Related]
32. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
Weinberg MA
Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
[TBL] [Abstract][Full Text] [Related]
33. Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex.
Gkountakos A; Pilotto S; Mafficini A; Vicentini C; Simbolo M; Milella M; Tortora G; Scarpa A; Bria E; Corbo V
Carcinogenesis; 2018 Jul; 39(8):971-980. PubMed ID: 29955840
[TBL] [Abstract][Full Text] [Related]
34. mTORC1 and mTORC2 coordinate early NK cell development by differentially inducing E4BP4 and T-bet.
Li D; Wang Y; Yang M; Dong Z
Cell Death Differ; 2021 Jun; 28(6):1900-1909. PubMed ID: 33462410
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia Increases IGFBP-1 Phosphorylation Mediated by mTOR Inhibition.
Damerill I; Biggar KK; Abu Shehab M; Li SS; Jansson T; Gupta MB
Mol Endocrinol; 2016 Feb; 30(2):201-16. PubMed ID: 26714229
[TBL] [Abstract][Full Text] [Related]
36. Disruption of the Scaffolding Function of mLST8 Selectively Inhibits mTORC2 Assembly and Function and Suppresses mTORC2-Dependent Tumor Growth
Hwang Y; Kim LC; Song W; Edwards DN; Cook RS; Chen J
Cancer Res; 2019 Jul; 79(13):3178-3184. PubMed ID: 31085701
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic Targeting of mTORC2 in mTORopathies.
Dentel B; Escamilla CO; Tsai PT
Neuron; 2019 Dec; 104(6):1032-1033. PubMed ID: 31951535
[TBL] [Abstract][Full Text] [Related]
38. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.
Zou Z; Chen J; Yang J; Bai X
Curr Cancer Drug Targets; 2016; 16(4):288-304. PubMed ID: 26563881
[TBL] [Abstract][Full Text] [Related]
39. mTORC1 and mTORC2 expression in inner retinal neurons and glial cells.
Losiewicz MK; Elghazi L; Fingar DC; Rajala RVS; Lentz SI; Fort PE; Abcouwer SF; Gardner TW
Exp Eye Res; 2020 Aug; 197():108131. PubMed ID: 32622801
[TBL] [Abstract][Full Text] [Related]
40. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
